Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PCRX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Bupivacaine FDA approved Oct 2011 · Exparel |
Laparotomy | Phase 4 · NCT03827291 | Completed |
| Liposomal Bupivacaine | Total Knee Arthroplasty | Phase 4 · NCT07584915 | Enrolling by invitation |
| Continuous popliteal nerve block with… | Moderate-to-severely Painful Ankle Surgery | Phase 4 · NCT06995352 | Enrolling by invitation |
| Bupivacaine supraclavicular block | Hand Injuries | Phase 4 · NCT02058303 | Terminated |
| Ketorolac | Pain | Phase 4 · NCT02128646 | Completed |
| Methadone | Adolescent Idiopathic Scoliosis | Phase 4 · NCT05730920 | Completed |
| Popliteal nerve block including liposomal… | Moderate-to-severely Painful Ankle Surgery | Phase 4 · NCT06995352 | Enrolling by invitation |
| Popliteal nerve block with exclusively… | Moderate-to-severely Painful Ankle Surgery | Phase 4 · NCT06995352 | Enrolling by invitation |
| Adductor canal nerve block with exclusively… | Moderate-to-severely Painful Ankle Surgery | Phase 4 · NCT06995352 | Enrolling by invitation |
| Adductor canal nerve block including liposomal… | Moderate-to-severely Painful Ankle Surgery | Phase 4 · NCT06995352 | Enrolling by invitation |
| Ropivacaine | Rotator Cuff Injury | Phase 4 · NCT03738696 | Completed |
| 0.25% bupivacaine (HCl): 30 ml | Total Ankle Arthroplasty | Phase 3 · NCT07212114 | Recruiting |
| FX006 | Osteoarthritis of the Knee | Phase 3 · NCT03046446 | Completed |
| Triamcinolone Acetonide Extended-Release… | Osteoarthritis of the Knee | Phase 3 · NCT02357459 | Completed |
| Bupivacain | Back Pain | Phase 2/3 · NCT06350981 | Enrolling by invitation |
| Bupivacaine Hydrochloride | Pain, Postoperative | Phase 2/3 · NCT06077422 | Enrolling by invitation |
Also used in these trials (approved or third-party drugs, not PCRX's own candidates): Triamcinolone Acetonide, Duloxetine, Acetaminophen, Celecoxib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
PCRX holds $295.6M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PCRX files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PCRX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →